Genmab soars to record highs after cancer drug succeeds in key trial

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 29 Oct, 16:06 UTC

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.

science

Sources

• T2Genmab soars to record highs after cancer drug succeeds in key trialBioPharma Dive / Healthcare Dive / MedTech Dive29 Oct, 16:06